PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Michiya Matsusaki Osaka University to Speak at Tissue Models Conference on May 6-7 in Berlin - Michiya Matsusaki, Assistant Professor at Osaka University, will speak about “Construction of Vascularized 3D Human Tissue Models and Their Applications for Drug Screening” at the Tissue Models & Drug Screening Conference, taking place May 6-7, 2014
Michiya Matsusaki Osaka University to Speak at Tissue Models Conference on May 6-7 in Berlin

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2014/01/27 - Michiya Matsusaki, Assistant Professor at Osaka University, will speak about “Construction of Vascularized 3D Human Tissue Models and Their Applications for Drug Screening” at the Tissue Models & Drug Screening Conference, taking place May 6-7, 2014.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Michiya Matsusaki, Assistant Professor at Osaka University, will speak about “Construction of Vascularized 3D Human Tissue Models and Their Applications for Drug Screening” at the Tissue Models & Drug Screening Conference, taking place May 6-7, 2014 in Berlin.

Developing artificial three-dimensional (3D) human tissues containing blood and lymph capillary networks is one of the key challenges in tissue engineering, and modulating 3D cell-cell interaction inside the 3D artificial tissues is a particularly significant issue. Dr. Matsusaki will share how his lab developed simple and unique bottom-up approaches using nanometer-sized, layer-by-layer films consisting of fibronectin and gelatin (FN-G) as a nanometer-sized extracellular matrix. The FN-G nanofilms were prepared directly on the cell surface and acted as a stable adhesive surface for interaction with the neighbor cells. This approach easily provided approximately 10 to 20 layered tissues and fully vascularized tissues, after only one day of incubation, and a sandwich culture of the endothelial cells obtained a width of over one centimeter.

When the lab used lymph endothelial cells together with blood endothelial cells, the individual capillary networks of blood and lymph capillaries were successfully obtained. Moreover, perfusable vascular networks, which have an opening pore at the surfaces, were constructed by controlling the cell location. Various molecules, nanoparticles, and blood cells were able to be injected into both the blood and lymph capillaries. These vascularized 3D tissues will be useful as an artificial human tissue model for tissue engineering and pharmaceutical applications.

Michiya Matsusaki received his Ph.D. degree in 2003 under the direction of Prof. Mitsuru Akashi from Kagoshima University, Japan. In 2005, he joined the Department of Applied Chemistry in the Graduate School of Engineering at Osaka University as a designated assistant professor. Since 2006, he has been an assistant professor of the department, where his research focus is on functional polymers and biomaterials for biomedical and tissue engineering applications.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Michiya Matsusaki Osaka University to Speak at Tissue Models Conference on May 6-7 in Berlin

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 kristen.starkey[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)